Article Text

Download PDFPDF
Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange
  1. Angel P Sempere1,
  2. Eloísa Feliu-Rey2,
  3. Rosa Sanchez-Perez1,
  4. Juan Nieto-Navarro3
  1. 1 Neurology Department, Hospital General Universitario de Alicante, Alicante, Spain
  2. 2 MRI Unit, Erescanner Salud, Alicante, Spain
  3. 3 Neurosurgery Department, Hospital General Universitario de Alicante, Alicante, Spain
  1. Correspondence to Dr AP Sempere, Neurology Department, Hospital General Universitario de Alicante, Alicante 03010, Spain; aperezs{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Case history

A 38-year-old woman with no significant past medical history presented with a generalised tonic–clonic seizure. The patient was afebrile and general physical and neurological examinations were normal. MRI of the brain revealed an irregular mass in the right temporal lobe with T2-weighted and fluid-attenuated inversion recovery (FLAIR) signal hyperintensity and heterogeneous enhancement after the administration of gadolinium (figure 1A–D). Laboratory investigations included normal blood count, liver enzymes, serum creatinine, angiotensin converting enzyme and erythrocyte sedimentation rate (ESR). Serum serologies for lyme, syphilis, viral hepatitis, brucella and HIV were negative. Tests for antinuclear antibodies, extractable nuclear antigens, rheumatoid factor and antinuclear cytoplasmic antibodies were negative. A chest and abdominal CT was normal. The patient was treated with levetiracetam and a biopsy …

View Full Text


  • Contributors APS conceived the idea for the article, performed the literature search and wrote the article. EF-R, RS-P and JN-N revised it critically for important intellectual content and gave final approval of the version to be published.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.